<DOC>
	<DOCNO>NCT00982345</DOCNO>
	<brief_summary>The purpose study find part brain increase decreased connectivity people depress Seroquel extend release ( XR ) change connectivity depress patient . The genetic sample collect look variation gene ( serotonin transporter gene ) , affect function chemical serotonin brain .</brief_summary>
	<brief_title>Brain Imaging Quetiapine Response Anxious Depression</brief_title>
	<detailed_description>This study measure activity connectivity different part brain , patient see picture , use Magnetic Resonance Imaging ( MRI ) scan . For study three MRI scan conduct . One patient begin medication , one study 3 week treatment one six week treatment seroquel .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent A diagnosis Major Depressive Episode Diagnostic Statistical Manual Mental Disorders Fourth Edition ( DSMIV ) Females Males age 18 60 year Female subject childbearing potential must use reliable method contraception negative serum human chorionic gonadotropin ( HCG ) test enrollment Able understand comply requirement study 17item Hamilton Depression Rating Scale ( HDRS ) score &gt; 15 Hamilton Anxiety Scale ( HAMA ) score &gt; 15 Satisfy criterion undergo MRI scan base MRI screen questionnaire Able manage outpatient initial assessment treatment ascertain follow : Symptoms worsen 10 point HDRS course study . No danger self others . Pregnancy lactation Meeting DSMIV criterion schizophrenia , schizophreniform disorder , schizoaffective disorder , atypical psychosis , mental retardation , organic mental ( include organic mood ) disorder Subjects , opinion investigator , pose imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate , judge investigator Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 inducers 14 day precede enrolment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomisation Substance alcohol dependence enrollment ( except dependence full remission , except caffeine nicotine dependence ) , define DSMIV criterion Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within four week prior enrollment Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrollment randomization treatment present study . Participation another drug trial within four week prior enrollment study long accordance local requirement A subject Diabetes Mellitus ; people develop hyperglycemia remove study An absolute neutrophil count ( ANC ) 1.5 x 109 per liter Use psychotropics past two week . If fluoxetine past , medication four week . History lack response Quetiapine extend release . Acutely suicidal homicidal require inpatient treatment . Metallic implant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Seroquel</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>fMRI</keyword>
	<keyword>picture</keyword>
</DOC>